{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T21:19:42Z","timestamp":1778793582585,"version":"3.51.4"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:00:00Z","timestamp":1762646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:00:00Z","timestamp":1762646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Pituitary adenoma, are common intracranial neoplasms that can exhibit invasive behavior, leading to increased morbidity, recurrence, and resistance to treatment. Identifying biomarkers associated with tumor invasiveness could improve early diagnosis and guide therapeutic interventions. This review evaluates molecular biomarkers linked to pituitary adenoma invasiveness and explores the potential of radiolabeling for noninvasive detection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search of PubMed and Embase databases was conducted to identify studies evaluating molecular markers associated with invasive pituitary adenoma. Biomarkers were selected based on their proposed role in tumor invasion, and evidence supporting their clinical relevance was summarized. Additionally, existing radiolabeling techniques for biomarker detection were reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Five key biomarker groups were identified: matrix metalloproteinases (MMPs), urokinase plasminogen activator (uPA) system, myosin 5\u00a0A (MYO5A), vascular endothelial growth factor (VEGF), and survivin. MMPs were strongly linked to extracellular matrix degradation and invasion, while uPA facilitated invasion via MMP activation. MYO5A and survivin were implicated in epithelial-mesenchymal transition and tumor motility, and VEGF promoted angiogenesis. Radiolabeling techniques for MMPs, uPA\/uPAR, VEGF, and survivin demonstrated feasibility for imaging tumor invasiveness, though limitations such as non-specific tracer accumulation remain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This review highlights the potential of molecular biomarkers in predicting pituitary adenoma invasiveness and the emerging role of radiolabeled probes in noninvasive imaging. Future research should focus on validating these biomarkers in longitudinal studies and refining radiolabeling techniques to improve diagnostic accuracy and therapeutic targeting of invasive pituitary adenomas.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11102-025-01598-x","type":"journal-article","created":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T14:42:51Z","timestamp":1762699371000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Radiolabeling molecular biomarkers of invasive pituitary adenomas: a narrative review"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0964-0063","authenticated-orcid":false,"given":"Charbel","family":"Marche","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia C. M.","family":"Knop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivashankar","family":"Khanapur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Suero Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattew","family":"McCord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Catalino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,9]]},"reference":[{"issue":"1","key":"1598_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","volume":"33","author":"SL Asa","year":"2022","unstructured":"Asa SL, Mete O, Perry A, Osamura RY (2022) Overview of the 2022 WHO classification of pituitary tumors. Endocr Pathol 33(1):6\u201326. https:\/\/doi.org\/10.1007\/s12022-022-09703-7","journal-title":"Endocr Pathol"},{"issue":"3","key":"1598_CR2","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/cncr.20412","volume":"101","author":"S Ezzat","year":"2004","unstructured":"Ezzat S et al (2004) The prevalence of pituitary adenomas: a systematic review. Cancer 101(3):613\u2013619. https:\/\/doi.org\/10.1002\/cncr.20412","journal-title":"Cancer"},{"issue":"3","key":"1598_CR3","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ecl.2020.04.002","volume":"49","author":"AF Daly","year":"2020","unstructured":"Daly AF, Beckers A (2020) The epidemiology of pituitary adenomas. Endocrinol Metab Clin North Am 49(3):347\u2013355. https:\/\/doi.org\/10.1016\/j.ecl.2020.04.002","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"2","key":"1598_CR4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ando.2012.03.039","volume":"73","author":"N Karavitaki","year":"2012","unstructured":"Karavitaki N (2012) Prevalence and incidence of pituitary adenomas. Ann Endocrinol 73(2):79\u201380. https:\/\/doi.org\/10.1016\/j.ando.2012.03.039","journal-title":"Ann Endocrinol"},{"issue":"1","key":"1598_CR5","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s11102-021-01189-6","volume":"25","author":"LE Castellanos","year":"2022","unstructured":"Castellanos LE, Gutierrez C, Smith T, Laws ER, Iorgulescu JB (2022) Epidemiology of common and uncommon adult pituitary tumors in the U.S. according to the 2017 World Health Organization classification. Pituitary 25(1):201\u2013209. https:\/\/doi.org\/10.1007\/s11102-021-01189-6","journal-title":"Pituitary"},{"issue":"1","key":"1598_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11102-010-0253-4","volume":"14","author":"BD McDowell","year":"2011","unstructured":"McDowell BD, Wallace RB, Carnahan RM, Chrischilles EA, Lynch CF, Schlechte JA (2011) Demographic differences in incidence for pituitary adenoma. Pituitary 14(1):23\u201330. https:\/\/doi.org\/10.1007\/s11102-010-0253-4","journal-title":"Pituitary"},{"issue":"3","key":"1598_CR7","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1007\/s12020-024-03877-2","volume":"85","author":"E Lefevre","year":"2024","unstructured":"Lefevre E, Chasseloup F, Hage M, Chanson P, Buchfelder M, Kamenick\u00fd P (2024) Clinical and therapeutic implications of cavernous sinus invasion in pituitary adenomas. Endocrine 85(3):1058\u20131065. https:\/\/doi.org\/10.1007\/s12020-024-03877-2","journal-title":"Endocrine"},{"issue":"8","key":"1598_CR8","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3275\/7618","volume":"34","author":"M Losa","year":"2011","unstructured":"Losa M, Picozzi P, Motta M, Valle M, Franzin A, Mortini P (2011) The role of radiation therapy in the management of non-functioning pituitary adenomas. J. Endocrinol Invest 34(8):623\u2013629. https:\/\/doi.org\/10.3275\/7618","journal-title":"J. Endocrinol Invest"},{"issue":"1","key":"1598_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2165\/00019053-200018010-00008","volume":"18","author":"B Jonsson","year":"2000","unstructured":"Jonsson B, Nilsson B (2000) The impact of pituitary adenoma on morbidity. Increased sick leave and disability retirement in a cross-sectional analysis of Swedish national data. Pharmacoeconomics 18(1):73\u201381. https:\/\/doi.org\/10.2165\/00019053-200018010-00008","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"1598_CR10","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1210\/clinem\/dgad098","volume":"108","author":"P Burman","year":"2023","unstructured":"Burman P, Casar-Borota O, Perez-Rivas LG, Dekkers OM (2023) Aggressive pituitary tumors and pituitary carcinomas: from pathology to treatment. J Clin Endocrinol Metab 108(7):1585\u20131601. https:\/\/doi.org\/10.1210\/clinem\/dgad098","journal-title":"J Clin Endocrinol Metab"},{"issue":"Supplement_5","key":"1598_CR11","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","volume":"24","author":"QT Ostrom","year":"2022","unstructured":"Ostrom QT et al (2022) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015\u20132019. Neuro-Oncol 24(Supplement_5):v1\u2013v95. https:\/\/doi.org\/10.1093\/neuonc\/noac202","journal-title":"Neuro-Oncol"},{"issue":"1","key":"1598_CR12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00401-013-1084-y","volume":"126","author":"J Trouillas","year":"2013","unstructured":"Trouillas J et al (2013) A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case\u2013control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 126(1):123\u2013135. https:\/\/doi.org\/10.1007\/s00401-013-1084-y","journal-title":"Acta Neuropathol"},{"key":"1598_CR13","unstructured":"Marche C (2024) Literature Review Search Tool. (Oct. Python. Accessed: Feb. 21, 2025. [Online]. Available: https:\/\/github.com\/Pituitary-Normal-Space\/database-searcher"},{"issue":"6","key":"1598_CR14","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3171\/jns.1986.65.6.0733","volume":"65","author":"BW Scheithauer","year":"1986","unstructured":"Scheithauer BW, Kovacs KT, Laws ER, Randall RV (1986) Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg 65(6):733\u2013744. https:\/\/doi.org\/10.3171\/jns.1986.65.6.0733","journal-title":"J Neurosurg"},{"key":"1598_CR15","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/978-3-642-77109-5_67","volume-title":"Neurosurgical standards cerebral aneurysms malignant gliomas","author":"M Buchfelder","year":"1992","unstructured":"Buchfelder M, Fahlbusch R, Adams EF, Roth M, Thierauf P (1992) Growth characteristics and proliferation parameters of invasive pituitary adenomas. In: Piscol K, Klinger M, Brock M (eds) in Neurosurgical standards cerebral aneurysms malignant gliomas. Springer, Berlin, Heidelberg, pp 381\u2013386. doi: https:\/\/doi.org\/10.1007\/978-3-642-77109-5_67."},{"issue":"2","key":"1598_CR16","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10143-014-0525-y","volume":"37","author":"TM Hansen","year":"2014","unstructured":"Hansen TM et al (2014) Invasive adenoma and pituitary carcinoma: a SEER database analysis. Neurosurg Rev 37(2):279\u2013286. https:\/\/doi.org\/10.1007\/s10143-014-0525-y","journal-title":"Neurosurg Rev"},{"issue":"9","key":"1598_CR17","first-page":"1307","volume":"12","author":"LS Blevins","year":"1998","unstructured":"Blevins LS, Verity DK, Allen G (1998) Aggressive pituitary tumors. Oncol Williston Park N 12(9):1307\u20131312 1315; discussion 1315\u20131318, Sep","journal-title":"Oncol Williston Park N"},{"issue":"6","key":"1598_CR18","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.3171\/2019.3.JNS19367","volume":"132","author":"A Micko","year":"2019","unstructured":"Micko A et al (2019) Challenging Knosp high-grade pituitary adenomas. J Neurosurg 132(6):1739\u20131746. https:\/\/doi.org\/10.3171\/2019.3.JNS19367","journal-title":"J Neurosurg"},{"issue":"5","key":"1598_CR19","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.3171\/2016.3.JNS153044","volume":"126","author":"MA Mooney","year":"2017","unstructured":"Mooney MA et al (2017) Interrater and intrarater reliability of the Knosp scale for pituitary adenoma grading. J Neurosurg 126(5):1714\u20131719. https:\/\/doi.org\/10.3171\/2016.3.JNS153044","journal-title":"J Neurosurg"},{"issue":"3","key":"1598_CR20","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s11102-020-01122-3","volume":"24","author":"Y Fang","year":"2021","unstructured":"Fang Y et al (2021) Diagnostic value of Knosp grade and modified Knosp grade for cavernous sinus invasion in pituitary adenomas: a systematic review and meta-analysis. Pituitary 24(3):457\u2013464. https:\/\/doi.org\/10.1007\/s11102-020-01122-3","journal-title":"Pituitary"},{"key":"1598_CR21","doi-asserted-by":"crossref","unstructured":"Ense\u00f1at J et al (2006) Predictive value of the Knosp classification in grading the surgical resection of invasive pituitary macroadenomas. A prospective study of 23 cases. Neurocir Astur Spain 17(6):519\u2013526","DOI":"10.1016\/S1130-1473(06)70315-3"},{"key":"1598_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.807040","volume":"11","author":"M Araujo-Castro","year":"2022","unstructured":"Araujo-Castro M, Acitores Cancela A, Vior C, Pascual-Corrales E, Rodr\u00edguez Berrocal V, Knosp R (2022) Revised-Knosp, and Hardy-Wilson classifications for the prediction of surgical outcomes in the endoscopic endonasal surgery of pituitary adenomas: study of 228 cases. Front Oncol 11:807040. https:\/\/doi.org\/10.3389\/fonc.2021.807040","journal-title":"Front Oncol"},{"issue":"11","key":"1598_CR23","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41574-021-00550-w","volume":"17","author":"G Raverot","year":"2021","unstructured":"Raverot G et al (2021) Aggressive pituitary tumours and pituitary carcinomas. Nat Rev Endocrinol 17(11):671\u2013684. https:\/\/doi.org\/10.1038\/s41574-021-00550-w","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"1598_CR24","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1210\/endrev\/bnac010","volume":"43","author":"S Melmed","year":"2022","unstructured":"Melmed S et al (2022) Clinical biology of the pituitary adenoma. Endocr Rev 43(6):1003\u20131037. https:\/\/doi.org\/10.1210\/endrev\/bnac010","journal-title":"Endocr Rev"},{"issue":"3","key":"1598_CR25","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3171\/jns.1986.64.3.0402","volume":"64","author":"WR Selman","year":"1986","unstructured":"Selman WR, Laws ER, Scheithauer BW, Carpenter SM (1986) The occurrence of dural invasion in pituitary adenomas. J Neurosurg 64(3):402\u2013407. https:\/\/doi.org\/10.3171\/jns.1986.64.3.0402","journal-title":"J Neurosurg"},{"issue":"184","key":"1598_CR26","doi-asserted-by":"publisher","DOI":"10.24976\/Discov.Med.202436184.90","volume":"36","author":"Y Yang","year":"2024","unstructured":"Yang Y, Huang F, Wu X, Huang C, Li Y (2024) Demethylation of TIMP2 and TIMP3 inhibits cell proliferation, migration, and invasion in pituitary adenomas. Discov Med 36(184):184. https:\/\/doi.org\/10.24976\/Discov.Med.202436184.90","journal-title":"Discov Med"},{"issue":"1","key":"1598_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11060-004-6150-9","volume":"74","author":"L Pan","year":"2005","unstructured":"Pan L, Chen Z, Liu Y, Zhao J (2005) Magnetic resonance imaging and biological markers in pituitary adenomas with invasion of the cavernous sinus space. J Neurooncol 74(1):71\u201376. https:\/\/doi.org\/10.1007\/s11060-004-6150-9","journal-title":"J Neurooncol"},{"key":"1598_CR28","unstructured":"Matrix Metalloproteinases and Their Inhibitors., Accessed Nov. 25, 2024. [Online]. Available: https:\/\/encyclopedia.pub\/entry\/6088"},{"issue":"24","key":"1598_CR29","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003904","volume":"95","author":"H-Y Liu","year":"2016","unstructured":"Liu H-Y, Gu W-J, Wang C-Z, Ji X-J, Mu Y-M (2016) Matrix metalloproteinase-9 and \u2013 2 and tissue inhibitor of matrix metalloproteinase-2 in invasive pituitary adenomas: a systematic review and meta-analysis of case\u2013control trials. Medicine 95(24):e3904. https:\/\/doi.org\/10.1097\/MD.0000000000003904","journal-title":"Medicine"},{"key":"1598_CR30","doi-asserted-by":"publisher","DOI":"10.21203\/rs.2.24007\/v1","author":"B Sun","year":"2020","unstructured":"Sun B, Dai C, Liu X, Wang R, Kang J (2020) Matrix metalloproteinase 9 for evaluating invasiveness and recurrence in pituitary adenoma patients: A Meta-analysis. Feb 19. https:\/\/doi.org\/10.21203\/rs.2.24007\/v1","journal-title":"Feb 19"},{"issue":"1","key":"1598_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/cbr.2018.2589","volume":"34","author":"H Guo","year":"2019","unstructured":"Guo H et al (2019) Expressions of matrix Metalloproteinases-9 and tissue inhibitor of Metalloproteinase-1 in pituitary adenomas and their relationships with prognosis. Cancer Biother Radiopharm 34(1):1\u20136. https:\/\/doi.org\/10.1089\/cbr.2018.2589","journal-title":"Cancer Biother Radiopharm"},{"issue":"1","key":"1598_CR32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11102-007-0066-2","volume":"11","author":"J Gong","year":"2008","unstructured":"Gong J et al (2008) Matrix metalloproteinase-9, a potential biological marker in invasive pituitary adenomas. Pituitary 11(1):37\u201348. https:\/\/doi.org\/10.1007\/s11102-007-0066-2","journal-title":"Pituitary"},{"issue":"1","key":"1598_CR33","doi-asserted-by":"publisher","DOI":"10.1530\/EO-24-0037","volume":"5","author":"AC Th\u00e9","year":"2025","unstructured":"Th\u00e9 AC, Freire B et al (2025) Expression of MMP-2, MMP-9 and TIMP-2 in pituitary tumors and their relationship with cavernous sinus invasion. Endocr Oncol 5(1):e240037. https:\/\/doi.org\/10.1530\/EO-24-0037","journal-title":"Endocr Oncol"},{"issue":"6","key":"1598_CR34","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1021\/bc010028f","volume":"12","author":"BK Giersing","year":"2001","unstructured":"Giersing BK, Rae MT, CarballidoBrea M, Williamson RA, Blower PJ (2001) Synthesis and characterization of 111In\u2009\u2013\u2009DTPA\u2009\u2013\u2009N-TIMP-2: a radiopharmaceutical for imaging matrix metalloproteinase expression. Bioconjug Chem 12(6):964\u2013971. https:\/\/doi.org\/10.1021\/bc010028f","journal-title":"Bioconjug Chem"},{"issue":"5","key":"1598_CR35","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1021\/mp400569k","volume":"11","author":"SMJ van Duijnhoven","year":"2014","unstructured":"van Duijnhoven SMJ et al (2014) Imaging of MMP activity in postischemic cardiac remodeling using radiolabeled MMP-2\/9 activatable peptide probes. Mol Pharm 11(5):1415\u20131423. https:\/\/doi.org\/10.1021\/mp400569k","journal-title":"Mol Pharm"},{"issue":"5","key":"1598_CR36","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/med.21308","volume":"34","author":"AH Mekkawy","year":"2014","unstructured":"Mekkawy AH, Pourgholami MH, Morris DL (2014) Involvement of urokinase-type plasminogen activator system in cancer: an overview. Med Res Rev 34(5):918\u2013956. https:\/\/doi.org\/10.1002\/med.21308","journal-title":"Med Res Rev"},{"key":"1598_CR37","doi-asserted-by":"publisher","unstructured":"Leurer C, Rabbani SA, Leurer C, Rabbani SA (2015) Plasminogen Activator System \u2014 Diagnostic, Prognostic and Therapeutic Implications in Breast Cancer, in A Concise Review of Molecular Pathology of Breast Cancer, IntechOpen. https:\/\/doi.org\/10.5772\/59429","DOI":"10.5772\/59429"},{"issue":"5","key":"1598_CR38","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3892\/ijo.13.5.893","volume":"13","author":"U Reuning","year":"1998","unstructured":"Reuning U et al (1998) Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). Int J Oncol 13(5):893\u20131799. https:\/\/doi.org\/10.3892\/ijo.13.5.893","journal-title":"Int J Oncol"},{"issue":"5","key":"1598_CR39","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00401-003-0747-5","volume":"106","author":"UJ Knappe","year":"2003","unstructured":"Knappe UJ, Hagel C, Lisboa BW, Wilczak W, L\u00fcdecke DK, Saeger W (2003) Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue. Acta Neuropathol (Berl) 106(5):471\u2013478. https:\/\/doi.org\/10.1007\/s00401-003-0747-5","journal-title":"Acta Neuropathol (Berl)"},{"issue":"7","key":"1598_CR40","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7150\/thno.3791","volume":"3","author":"M Ploug","year":"2013","unstructured":"Ploug M (2013) Structure-driven design of radionuclide tracers for non-invasive imaging of uPAR and targeted radiotherapy. The tale of a synthetic peptide antagonist. Theranostics 3(7):467\u2013476. https:\/\/doi.org\/10.7150\/thno.3791","journal-title":"Theranostics"},{"key":"1598_CR41","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.humpath.2018.06.002","volume":"80","author":"N Sato","year":"2018","unstructured":"Sato N et al (2018) Myosin 5a regulates tumor migration and epithelial-mesenchymal transition in esophageal squamous cell carcinoma: utility as a prognostic factor. Hum Pathol 80:113\u2013122. https:\/\/doi.org\/10.1016\/j.humpath.2018.06.002","journal-title":"Hum Pathol"},{"issue":"1","key":"1598_CR42","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/ijc.24641","volume":"126","author":"L Lan","year":"2010","unstructured":"Lan L et al (2010) Upregulation of myosin Va by snail is involved in cancer cell migration and metastasis. Int J Cancer 126(1):53\u201364. https:\/\/doi.org\/10.1002\/ijc.24641","journal-title":"Int J Cancer"},{"issue":"2","key":"1598_CR43","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1677\/ERC-10-0018","volume":"17","author":"F Galland","year":"2010","unstructured":"Galland F et al (2010) Differential gene expression profiles of invasive and non-invasive non-functioning pituitary adenomas based on microarray analysis. Endocr Relat Cancer 17(2):361\u2013371. https:\/\/doi.org\/10.1677\/ERC-10-0018","journal-title":"Endocr Relat Cancer"},{"key":"1598_CR44","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.semcancer.2022.03.011","volume":"86","author":"Y Yang","year":"2022","unstructured":"Yang Y, Cao Y (2022) The impact of VEGF on cancer metastasis and systemic disease. Semin Cancer Biol 86:251\u2013261. https:\/\/doi.org\/10.1016\/j.semcancer.2022.03.011","journal-title":"Semin Cancer Biol"},{"key":"1598_CR45","doi-asserted-by":"publisher","unstructured":"Liu W, Xu J, Wang M, Wang Q, Bi Y, Han M (2011) Tumor-derived vascular endothelial growth factor (VEGF)-A facilitates tumor metastasis through the VEGF-VEGFR1 signaling pathway. Int J Oncol 39(5):1213\u20131220. https:\/\/doi.org\/10.3892\/ijo.2011.1138","DOI":"10.3892\/ijo.2011.1138"},{"key":"1598_CR46","unstructured":"Kopparapu PK et al (2013) Expression of VEGF and its receptors VEGFR1\/VEGFR2 is associated with invasiveness of bladder cancer. Anticancer Res33(6):2381\u20132390"},{"issue":"4","key":"1598_CR47","first-page":"775","volume":"5","author":"ER Sauter","year":"1999","unstructured":"Sauter ER, Nesbit M, Watson JC, Klein-Szanto A, Litwin S, Herlyn M (1999) Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck. Clin Cancer Res Off J Am Assoc Cancer Res 5(4):775\u2013782","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"6","key":"1598_CR48","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2217\/pme.13.61","volume":"10","author":"C Tanase","year":"2013","unstructured":"Tanase C et al (2013) Angiogenic markers: molecular targets for personalized medicine in pituitary adenoma. Personal Med 10(6):539\u2013548. https:\/\/doi.org\/10.2217\/pme.13.61","journal-title":"Personal Med"},{"issue":"5","key":"1598_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8050695","volume":"8","author":"M Sato","year":"2019","unstructured":"Sato M et al (2019) Analysis of tumor angiogenesis and immune microenvironment in non-functional pituitary endocrine tumors. J Clin Med 8(5):5. https:\/\/doi.org\/10.3390\/jcm8050695","journal-title":"J Clin Med"},{"issue":"2","key":"1598_CR50","doi-asserted-by":"publisher","first-page":"2","DOI":"10.5603\/EP.a2018.0001","volume":"69","author":"A Baldys-Waligorska","year":"2018","unstructured":"Baldys-Waligorska A, Wierzbicka I, Sokolowski G, Adamek D, Golkowski F (2018) Markers of proliferation and invasiveness in somatotropinomas. Endokrynol Pol 69(2):2. https:\/\/doi.org\/10.5603\/EP.a2018.0001","journal-title":"Endokrynol Pol"},{"key":"1598_CR51","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.gene.2016.12.012","volume":"603","author":"W He","year":"2017","unstructured":"He W et al (2017) Relationship between RSUME and HIF-1\u03b1\/VEGF-A with invasion of pituitary adenoma. Gene 603:54\u201360. https:\/\/doi.org\/10.1016\/j.gene.2016.12.012","journal-title":"Gene"},{"issue":"3","key":"1598_CR52","doi-asserted-by":"publisher","first-page":"380","DOI":"10.5137\/1019-5149.JTN.9347-13.1","volume":"25","author":"M Yilmaz","year":"2015","unstructured":"Yilmaz M, Vural E, Koc K, Ceylan S (2015) Cavernous sinus invasion and effect of immunohistochemical features on remission in growth hormone secreting pituitary adenomas. Turk Neurosurg 25(3):380\u2013388. https:\/\/doi.org\/10.5137\/1019-5149.JTN.9347-13.1","journal-title":"Turk Neurosurg"},{"issue":"3","key":"1598_CR53","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s11102-012-0434-4","volume":"16","author":"R S\u00e1nchez-Ortiga","year":"2013","unstructured":"S\u00e1nchez-Ortiga R, S\u00e1nchez-Tejada L, Moreno-Perez O, Riesgo P, Niveiro M, PicoAlfonso AM (2013) Over-expression of vascular endothelial growth factor in pituitary adenomas is associated with extrasellar growth and recurrence. Pituitary 16(3):370\u2013377. https:\/\/doi.org\/10.1007\/s11102-012-0434-4","journal-title":"Pituitary"},{"issue":"6","key":"1598_CR54","first-page":"823","volume":"31","author":"S Yarman","year":"2010","unstructured":"Yarman S, Kurtulmus N, Canbolat A, Bayindir C, Bilgic B, Ince N (2010) Expression of Ki-67, p53 and vascular endothelial growth factor (VEGF) concomitantly in growth hormone-secreting pituitary adenomas; which one has a role in tumor behavior\u202f? Neuro Endocrinol Lett 31(6):823\u2013828","journal-title":"Neuro Endocrinol Lett"},{"issue":"2","key":"1598_CR55","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1530\/eje.1.01843","volume":"152","author":"SA Borg","year":"2005","unstructured":"Borg SA, Kerry KE, Royds JA, Battersby RD, Jones TH (2005) Correlation of VEGF production with IL1 alpha and IL6 secretion by human pituitary adenoma cells. Eur J Endocrinol 152(2):293\u2013300. https:\/\/doi.org\/10.1530\/eje.1.01843","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"1598_CR56","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s007010070003","volume":"142","author":"T Iuchi","year":"2000","unstructured":"Iuchi T, Saeki N, Osato K, Yamaura A (2000) Proliferation, vascular endothelial growth factor expression and cavernous sinus invasion in growth hormone secreting pituitary adenomas. Acta Neurochir. (Wien) 142(12):1345\u20131351. https:\/\/doi.org\/10.1007\/s007010070003","journal-title":"Acta Neurochir. (Wien)"},{"issue":"6","key":"1598_CR57","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.3892\/ijo.2017.3989","volume":"50","author":"F Galli","year":"2017","unstructured":"Galli F et al (2017) Radiolabeling of VEGF165 with 99mTc to evaluate VEGFR expression in tumor angiogenesis. Int J Oncol 50(6):2171\u20132179. https:\/\/doi.org\/10.3892\/ijo.2017.3989","journal-title":"Int J Oncol"},{"key":"1598_CR58","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.apradiso.2009.02.006","volume":"67","author":"S-Y Lee","year":"2009","unstructured":"Lee S-Y, Hong Y-D, Pyun M-S, Felipe PM, Choi S-J (2009) Radiolabeling of monoclonal anti-vascular endothelial growth factor receptor 1 (VEGFR 1) with (177)Lu for potential use in radioimmunotherapy. Appl Radiat Isot Data Instrum Methods Use Agric Ind Med 67:7\u20138. https:\/\/doi.org\/10.1016\/j.apradiso.2009.02.006","journal-title":"Appl Radiat Isot Data Instrum Methods Use Agric Ind Med"},{"issue":"11","key":"1598_CR59","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.2967\/jnumed.116.173237","volume":"57","author":"J-P Meyer","year":"2016","unstructured":"Meyer J-P, Edwards KJ, Kozlowski P, Backer MV, Backer JM, Lewis JS (2016) Selective imaging of VEGFR-1 and VEGFR-2 using 89Zr-labeled single-chain VEGF mutants. J Nucl Med 57(11):1811\u20131816. https:\/\/doi.org\/10.2967\/jnumed.116.173237","journal-title":"J Nucl Med"},{"key":"1598_CR60","unstructured":"Cai W et al (2006) PET of Vascular Endothelial Growth Factor Receptor Expression. J Nucl Med 47(12)2048\u20132056"},{"issue":"10","key":"1598_CR61","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1021\/acs.bioconjchem.2c00272","volume":"33","author":"P Barta","year":"2022","unstructured":"Barta P et al (2022) Preparation, in vitro affinity, and in vivo biodistribution of receptor-specific 68Ga-labeled peptides targeting vascular endothelial growth factor receptors. Bioconjug Chem 33(10):1825\u20131836. https:\/\/doi.org\/10.1021\/acs.bioconjchem.2c00272","journal-title":"Bioconjug Chem"},{"issue":"20","key":"1598_CR62","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.2174\/138161212800672796","volume":"18","author":"T Kniess","year":"2012","unstructured":"Kniess T (2012) Radiolabeled small molecule inhibitors of VEGFR. Curr Pharm Des 18(20):2867\u20132874. https:\/\/doi.org\/10.2174\/138161212800672796","journal-title":"Curr Pharm Des"},{"issue":"8","key":"1598_CR63","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.2967\/jnumed.107.041301","volume":"48","author":"WB Nagengast","year":"2007","unstructured":"Nagengast WB et al (2007) In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 48(8):1313\u20131319. https:\/\/doi.org\/10.2967\/jnumed.107.041301","journal-title":"J Nucl Med"},{"issue":"389","key":"1598_CR64","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aab1624","volume":"8","author":"DB Rivadeneira","year":"2015","unstructured":"Rivadeneira DB et al (2015) Survivin promotes oxidative phosphorylation, subcellular mitochondrial repositioning, and tumor cell invasion. Sci Signal 8(389):ra80\u2013ra80. https:\/\/doi.org\/10.1126\/scisignal.aab1624","journal-title":"Sci Signal"},{"issue":"1","key":"1598_CR65","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ccr.2009.11.021","volume":"17","author":"S Mehrotra","year":"2010","unstructured":"Mehrotra S, Languino LR, Raskett CM, Mercurio AM, Dohi T, Altieri DC (2010) IAP regulation of metastasis. Cancer Cell 17(1):53\u201364. https:\/\/doi.org\/10.1016\/j.ccr.2009.11.021","journal-title":"Cancer Cell"},{"issue":"62","key":"1598_CR66","doi-asserted-by":"publisher","first-page":"105637","DOI":"10.18632\/oncotarget.22354","volume":"8","author":"X Kong","year":"2017","unstructured":"Kong X et al (2017) Survivin overexpression is potentially associated with pituitary adenoma invasiveness. Oncotarget 8(62):105637\u2013105647. https:\/\/doi.org\/10.18632\/oncotarget.22354","journal-title":"Oncotarget"},{"issue":"3","key":"1598_CR67","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.bmcl.2015.12.046","volume":"26","author":"T Fuchigami","year":"2016","unstructured":"Fuchigami T et al (2016) Synthesis and evaluation of a radioiodinated 4,6-diaryl-3-cyano-2-pyridinone derivative as a survivin targeting SPECT probe for tumor imaging. Bioorg Med Chem Lett 26(3):999\u20131004. https:\/\/doi.org\/10.1016\/j.bmcl.2015.12.046","journal-title":"Bioorg Med Chem Lett"},{"issue":"12","key":"1598_CR68","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1016\/j.bmc.2018.04.034","volume":"26","author":"N Ishikawa","year":"2018","unstructured":"Ishikawa N, Fuchigami T, Mizoguchi T, Yoshida S, Haratake M, Nakayama M (2018) Synthesis and characterization of radioiodinated 3-phenethyl-2-indolinone derivatives for SPECT imaging of survivin in tumors. Bioorg Med Chem 26(12):3111\u20133116. https:\/\/doi.org\/10.1016\/j.bmc.2018.04.034","journal-title":"Bioorg Med Chem"},{"issue":"12","key":"1598_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10123178","volume":"10","author":"I Ivkovi\u0107","year":"2022","unstructured":"Ivkovi\u0107 I, Limani Z, Jakov\u010devi\u0107 A, Hui\u0107 D, Prgomet D (2022) Role of matrix metalloproteinases and their inhibitors in locally invasive papillary thyroid cancer. Biomedicines 10(12):3178. https:\/\/doi.org\/10.3390\/biomedicines10123178","journal-title":"Biomedicines"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01598-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-025-01598-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01598-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T08:47:09Z","timestamp":1765961229000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-025-01598-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,9]]},"references-count":69,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1598"],"URL":"https:\/\/doi.org\/10.1007\/s11102-025-01598-x","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,9]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"126"}}